- Conditions
- Squamous Cell Carcinoma (SCC), Recurrent or Metastatic, Platinum-refractory Cervical Cancer
- Interventions
- Cemiplimab, Investigator Choice (IC) Chemotherapy
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Orange, California + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 48
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Small Cell Lung Cancer, Pancreatic Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer
- Interventions
- Topotecan and pegylated doxorubicin
- Drug
- Lead sponsor
- Christiana Care Health Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Newark, Delaware
- Conditions
- Platinum-resistant Ovarian Cancer
- Interventions
- Rina-S, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin (PLD), Gemcitabine
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 72
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 60 more
- Conditions
- Mediastinal Neoplasms
- Interventions
- Intravenous Topotecan, Intravenous Docetaxel
- Drug
- Lead sponsor
- Aultman Health Foundation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Canton, Ohio
- Conditions
- Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor
- Interventions
- alisertib, methotrexate, cisplatin, carboplatin, cyclophosphamide, etoposide, topotecan, vincristine, Surgical resection, Radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 9
- States / cities
- Palo Alto, California • San Diego, California • Aurora, Colorado + 6 more
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Solid Tumors
- Interventions
- Idasanutlin, Venetoclax, Cyclophosphamide, Topotecan, Fludarabine, Cytarabine, Intrathecal Chemotherapy
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 0 Years to 30 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Palo Alto, California • Orlando, Florida + 2 more
- Conditions
- Central Nervous System (CNS) Metastases, Brain Metastases
- Interventions
- Topotecan, Temozolomide
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years to 79 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Neuroblastoma
- Interventions
- Topotecan, Cyclophosphamide, Cisplatin, Etoposide, Vincristine, Doxorubicin, Sargramostim
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 12 Months to 18 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 2
- States / cities
- San Diego, California • Houston, Texas
- Conditions
- Retinoblastoma
- Interventions
- subtenon Carboplatin, Topotecan Hydrochloride, Vincristine, Filgrastim
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Up to 10 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Small Cell Lung Cancer
- Interventions
- Rovalpituzumab tesirine, Topotecan, Dexamethasone
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 444 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 31
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 28 more
- Conditions
- Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer
- Interventions
- Topotecan, Gemcitabine
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 15
- States / cities
- Los Gatos, California • Santa Rosa, California • Washington D.C., District of Columbia + 12 more
- Conditions
- Ovarian Cancer
- Interventions
- SGI-110, Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine), Carboplatin
- Drug
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Gainesville, Florida • Augusta, Georgia + 10 more
- Conditions
- Ovarian Cancer
- Interventions
- NMS-03305293, Topotecan
- Drug
- Lead sponsor
- Nerviano Medical Sciences
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 5
- States / cities
- Peoria, Illinois • St Louis, Missouri • Philadelphia, Pennsylvania + 2 more
- Conditions
- Lung Cancer
- Interventions
- bevacizumab, topotecan hydrochloride
- Biological · Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Saint Louis Park, Minnesota
- Conditions
- Neoplasms, Breast
- Interventions
- capecitabine, topotecan, lapatinib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 13
- States / cities
- Washington D.C., District of Columbia • Indianapolis, Indiana • Sioux City, Iowa + 10 more
- Conditions
- Lung Cancer, Small Cell
- Interventions
- topotecan, carboplatin
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 12
- States / cities
- Tucson, Arizona • Concord, California • Sacramento, California + 9 more
- Conditions
- Solid Cancer
- Interventions
- R-DXd, Paclitaxel, Topotecan, PLD
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 860 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 43
- States / cities
- Anchorage, Alaska • New Haven, Connecticut • Coral Gables, Florida + 32 more
- Conditions
- Cervical Cancer
- Interventions
- tisotumab vedotin, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 53
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 28 more
- Conditions
- Cancer
- Interventions
- topotecan
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma
- Interventions
- Palbociclib, Temozolomide, Irinotecan, Topotecan, Cyclophosphamide
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 37 more
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- Tarlatamab, Lurbinectedin, Topotecan, Amrubicin
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 509 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 25
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 19 more
- Conditions
- Solid Tumors
- Interventions
- Iniparib (SAR240550/BSI-201), Carboplatin, Doxorubicin HCL liposome injection, Gemcitabine, Irinotecan, Paclitaxel, Topotecan
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Santa Maria, California • Vallejo, California + 25 more
- Conditions
- Neuroblastoma, Bone Marrow, Sympathetic Nervous System
- Interventions
- cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- exatecan mesylate
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2000
- U.S. locations
- 1
- States / cities
- Houston, Texas